N-Isopropyl-N-neopentylamin | 69993-84-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Isopropyl-N-neopentylamin
• 英文别名: Neopentylisopropylamine；2,2-dimethyl-N-propan-2-ylpropan-1-amine
• CAS: 69993-84-6
• 化学式: C₈H₁₉N
• 分子量: 129.246
• InChiKey: BWHQHJPJPNECDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-isopropylpivalamide 生成 N-Isopropyl-N-neopentylamin
  参考文献：
  名称：

  15 n 13 c自旋自旋耦合常数的构象依赖性。

  摘要：

  已经制备了带有15 N标记的2-氮杂双环（2.2.2）辛烷-3-一1，N-异丙基新戊酰酰胺2和4-氮杂三环（4.3.1.1 3,8）十一烷-5-一3。将酰胺还原为相应的胺2-氮杂双-闭（2.2.2）辛烷4，N-异丙基-N-新戊胺5和4-氮杂三环（4.3.1.1 3,8）十一烷6。测量了这些化合物及其盐酸盐的13 C光谱，并根据其构象依赖性解释了15 N 13 C自旋耦合常数。

  DOI：

  10.1016/0040-4020(78)87011-2

文献信息

• Cationic Aluminium Complexes as Catalysts for Imine Hydrogenation
  作者：Alexander Friedrich、Jonathan Eyselein、Holger Elsen、Jens Langer、Jürgen Pahl、Michael Wiesinger、Sjoerd Harder

  DOI：10.1002/chem.202100641

  日期：2021.5.17

  Lewis acidic cationic aluminium complexes, stabilized by β–diketiminate (BDI) ligands and free of Lewis bases, have been prepared as their B(C6F5)4− salts and were investigated for catalytic activity in imine hydrogenation. The backbone (R1) and N (R2) substituents on the R1,R2BDI ligand (R1,R2BDI=HC[C(R1)N(R2)]2) influence sterics and Lewis acidity. Ligand bulk increases along the row Me,DIPPBDI

  强路易斯酸性阳离子铝络合物，通过β-二亚胺基（BDI）的配体和游离的路易斯碱稳定的，已被制备成其B（C 6 ˚F 5）4 -的盐和被研究用于亚胺氢化的催化活性。R1，R2 BDI配体（R1，R2 BDI = HC [C（R1）N（R2）] 2）上的主链（R1）和N（R2）取代基会影响空间和路易斯酸度。配体沿着行体积增大Me中，DIPP BDI <我，DIPeP BDI≈吨卜，DIPP BDI <吨卜，DIPeP BDI; DIPP = 2,6‐C（H）Me 2‐苯基，DIPeP = 2,6‐C（H）Et 2-苯基。Gutmann-Beckett检验显示的受主数为：（t Bu，DIPP BDI）AlMe + 85.6，（t Bu，DIPeP BDI）AlMe + 85.9，（Me，DIPP BDI）AlMe + 89.7，（Me，DIPeP BDI）AlMe + 90.8，（Me，DIPP BDI）AlH
• Diaryl piperidines as CB1 modulators
  申请人：Scott D. Jack

  公开号：US20070203183A1

  公开（公告）日：2007-08-30

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.

  具有通式（I）的一种化合物，或其药学上可接受的盐、溶剂合物或酯，可用于治疗代谢综合征（例如肥胖、腰围、脂质谱和胰岛素敏感性）、神经炎症性疾病、认知障碍、精神病、成瘾行为、胃肠道疾病和心血管疾病等疾病、疾病或症状。
• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• Naphthyridine derivatives having inhibitory activity against hiv integrase
  申请人：Taishi Teruhiko

  公开号：US20090227621A1

  公开（公告）日：2009-09-10

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R 1 is optionally substituted aralkyl; R 2 and R 3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R 4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  【需要解决的问题】提供一种具有抗病毒活性，特别是对HIV整合酶具有抑制活性的新型化合物，以及包含该化合物的制药组合物，特别是抗HIV药物。 【解决问题的方法】 化合物的化学式为：（其中：R1是可选取代的芳基甲基；R2和R3分别是氢、可选取代的烷基、可选取代的氨基、可选取代的烯基或可选取代的烷氧基（提供“可选取代”中的每个取代基均为非环状基）；R4是氢、可选取代的羧基、可选取代的甲酰胺基、可选取代的氨基甲酰胺基、可选取代的氨基（在“可选取代的甲酰胺基”、“可选取代的氨基甲酰胺基”和“可选取代的氨基”中，氨基上的取代基可以与相邻的N原子一起形成一个含有可选取代的N原子的杂环环），可选取代的烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环芳基）或其盐。
• INTERMEDIATES FOR MACROCYCLIC COMPOUNDS
  申请人：Marsault Eric

  公开号：US20090240027A1

  公开（公告）日：2009-09-24

  The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

  本发明涉及公式（I）的新型大环化合物及其药学上可接受的盐、水合物或溶剂化物：其中R1、R2、R3、R4、R5、R6、n1、m、p、Z1、Z2和Z3如规范中所述。本发明还涉及公式（I）的化合物，其为胃动素受体拮抗剂，并可用于治疗与该受体及运动功能障碍相关的疾病。